Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin and Dasatinib for Epigenetic Aging
NCT04946383Phase 2Unknown
- Sponsor
- TruDiagnostic
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib and quercetin in aging, sponsored by TruDiagnostic. Primary endpoint: Epigenetic Age Test at 6 months. Status: unknown.
02
Drugs
dasatinibquercetin
03
Conditions
aging
Beyond the preview
Go deeper on NCT04946383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946383.